公开(公告)号：US20210220404A1

公开(公告)日：2021-07-22

申请号：US17104983

申请日：2020-11-25

Applicant: Michael R. Greene ,  Novartis AG

Inventor： Aida Abujoub ,  John Blankenship ,  Attilio Bondanza ,  Jennifer Brogdon ,  Dexiu Bu ,  Serena De Vita ,  Glenn Dranoff ,  Boris Engels ,  Tony Fleming ,  Brian Walter Granda ,  Michael R. Greene ,  Carla Patricia Guimaraes ,  Anniesha Hack ,  Brian Holmberg ,  Connie Hong ,  Lu Huang ,  Olja Kodrasi ,  Joni Waiee Lam ,  Hyungwook Lim ,  Elizabeth Dorothy Pratico ,  Andrew Price ,  Akash Sohoni ,  Andrew Marc Stein ,  Louise Treanor ,  Chonghui Zhang ,  Xu Zhu

IPC: A61K35/17 ,  C07K16/28 ,  A61P35/00 ,  A61K45/06 ,  A61K39/395 ,  C07K14/705 ,  A61K38/17 ,  C12N5/0783 ,  C07K14/725

Abstract: The invention provides immune effector cells (for example, T cells, NK cells) that express a chimeric antigen receptor (CAR), and compositions and methods thereof.

公开(公告)号：US11779649B2

公开(公告)日：2023-10-10

申请号：US16718866

申请日：2019-12-18

Applicant: Novartis AG

Inventor： Matthew Burger ,  Joseph Anthony D'Alessio ,  Tony Fleming ,  Vivek Rauniyar ,  Eusebio Manchado Robles ,  Christian Kunz ,  Markus Waldhuber

IPC: A61K47/68 ,  A61P35/00 ,  A61K31/4745 ,  C07K16/18 ,  A61K45/06

CPC classification number: A61K47/6803 ,  A61K31/4745 ,  A61P35/00 ,  C07K16/18 ,  A61K45/06

Abstract: This application discloses anti-PMEL17 antibodies, antigen binding fragments thereof, and antibody drug conjugates comprising antibodies or antigen binding fragments conjugated to a GNAQ/GNA11 inhibitor. The application also discloses methods of treating or preventing cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.

公开(公告)号：US20230250179A1

公开(公告)日：2023-08-10

申请号：US18170941

申请日：2023-02-17

Applicant: Novartis AG

Inventor： Aida Abujoub ,  John Blankenship ,  Dexiu Bu ,  Tony Fleming ,  Brian Holmberg ,  Connie Hong ,  Lu Huang ,  Chonghui Zhang

IPC: C07K16/28 ,  A61P35/00 ,  A61K35/17 ,  C07K14/725 ,  C07K14/705 ,  C12N5/0783

CPC classification number: C07K16/2878 ,  A61P35/00 ,  A61K35/17 ,  C07K14/7051 ,  C07K14/70578 ,  C12N5/0636 ,  A61K38/00

Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA, vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.

公开(公告)号：US11492409B2

公开(公告)日：2022-11-08

申请号：US16426914

申请日：2019-05-30

Applicant: NOVARTIS AG

Inventor： Aida Abujoub ,  John Blankenship ,  Tony Fleming ,  Brian Holmberg ,  Connie Hong ,  Lu Huang ,  Haihui Lu

IPC: C07K16/28 ,  C07K16/30 ,  C07K16/46 ,  C07K14/715 ,  C07K14/725 ,  C07K14/735 ,  A61K39/395 ,  A61K47/68 ,  A61P35/00 ,  A61K39/00

Abstract: The present disclosure provides BCMA binding molecules that specifically bind to human BCMA, conjugates comprising the BCMA binding molecules, and pharmaceutical compositions comprising the BCMA binding molecules and the conjugates. The disclosure further provides methods of using the BCMA binding molecules to treat cancers that express cell surface BCMA. The disclosure yet further provides recombinant host cells engineered to express the BCMA binding molecules and methods of producing the BCMA binding molecules by culturing the host cells under conditions in which the BCMA binding molecules are expressed.

公开(公告)号：US20190382500A1

公开(公告)日：2019-12-19

申请号：US16439495

申请日：2019-06-12

Applicant: Novartis AG

Inventor： Aida Abujoub ,  John Blankenship ,  Dexiu Bu ,  Tony Fleming ,  Brian Holmberg ,  Connie Hong ,  Lu Huang ,  Chonghui Zhang

IPC: C07K16/28 ,  C07K14/725 ,  C07K14/705 ,  C12N5/0783 ,  A61P35/00 ,  A61K35/17

Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA, vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.